US Developer Of Non-Surgical Skin Cancer Treatment Opening Tel Aviv Office
February 7, 2018 | Florida-based medical device company Sensus Healthcare, a developer of non-invasive treatment of non-melanoma skin cancers using superficial radiation therapy (SRT), announced on Wednesday that it was opening an office in Tel Aviv to expand its footprint in the Middle East and Europe. Sensus Healthcare CEO Joe Sardano said opening an office in Israel, “the epicenter of cutting-edge aesthetic dermatology,” is an “obvious and natural next step” for the company as it seeks to bring its SRT-100 Vision systems, currently installed at Beilinson Hospital in Petah Tikva and Ichilov Hospital in Tel Aviv, to the world. Sensus Healthcare’s CTO Kal Fishman said, “A deeper foothold in Israel gives us access to collaborate with some of the most creative minds in the industry, which will ultimately help us to improve our technologies and expand our footprint across the globe.” He added, “Sensus’ commitment to non-invasive dermatological technology makes entering this progressive market a very logical choice.” The SRT-100 Vision system “features a unique integration of multimodality therapy and image-guidance technologies with software integration to provide enhanced precision, safety and quality in delivering SRT, electronic brachytherapy (eBx) and Grenz Ray therapy (GRT) in a seamlessly integrated and scalable platform,” according to a company statement. It received FDA clearance for the treatment of non-melanoma skin cancers and keloids in 2015.